Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,162 across all filing types
Latest filing 2026-06-05 Declaration of Voting R…
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K, Item 5.07 "Submission of Matters to a Vote of Security Holders," containing detailed vote tallies from the Annual Meeting (election of directors, ratification of auditor, advisory vote on executive compensation). This clearly matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-05 English
10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)
Interim / Quarterly Report
2026-05-07 English
8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by PTC Therapeutics, Inc. It reports positive topline results from a 24-month interim analysis study and announces a virtual presentation. The document includes a press release and a corporate presentation as exhibits. The text explicitly states that the presentation will be webcast and that the press release and slide presentation are furnished as exhibits. There are no detailed financial statements or substantive financial data within the text itself, only references to the press release and presentation. The document is relatively short (4598 characters) and serves as an announcement of results and an upcoming presentation rather than a full financial report or earnings release. This fits best with the category of Investor Presentation (IP), as the main content is about a corporate presentation and study results shared with investors. It is not an Earnings Release (ER) because it does not provide key financial highlights or quarterly results, nor is it an Interim Report (IR) because it lacks comprehensive financial statements. It is also not a Report Publication Announcement (RPA) because it includes substantive information about the study results and presentation, not just a notice of report availability.
2026-04-28 English
SCHEDULE 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
Director's Dealing
2026-03-27 English
3 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
Director's Dealing
2026-03-27 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.